minoxidil
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1786
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
February 11, 2026
Different Patterns of Lichen Planus in Three Members of One Family.
(PubMed, Case Rep Dermatol Med)
- "Patients were treated with an individualized plan that included sunscreen use, potent topical corticosteroids, topical pimecrolimus, minoxidil, and systemic finasteride. To our knowledge, no other family in the literature has been reported to have such a wide range of LP variants. This series underscores the need for further research into genetic and environmental factors contributing to the development of LP and its variants."
Journal • Alopecia • Dermatology • Dermatopathology • Fibrosis • Immunology • Lichen Planus
February 09, 2026
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of Androgenetic Alopecia.
(PubMed, J Cosmet Dermatol)
- "Microneedling exerts therapeutic effects by regulating hair growth signaling pathways and promoting transdermal drug delivery. It is effective for mild AGA when used alone, and achieves more significant efficacy in moderate to severe AGA when combined with drugs, with high safety. Thus, it is worthy of clinical promotion. However, this study has limitations such as a small sample size and male-only participants, and further multi-center, large-sample RCTs are needed for validation."
Journal • Alopecia • Dermatology • Immunology
February 09, 2026
Lipid-based nanocarriers coupled with CO2 laser-mediated drug delivery enhance skin penetration and hair follicle targeting.
(PubMed, J Drug Target)
- "The topical administration of hydrophilic drugs such as minoxidil and minocycline for alopecia and acne treatments remains unsatisfactory due to limited skin absorption and follicular uptake. In an in vivo Cutibacterium acnes-infected mouse model, a 2-log reduction in bacterial colony in the skin was observed with the combined laser and NLC. Our preclinical evidence demonstrates that the combination of laser ablation with specific nanoformulations appears to be an effective and safe strategy for cutaneous and follicular delivery of hydrophilic drugs."
Journal • Acne Vulgaris • Aesthetic Medicine • Alopecia • Immunology
January 05, 2026
Update on oral minoxidil
(AAD 2026)
- No abstract available
January 05, 2026
Minoxidil: what you need to know!
(AAD 2026)
- No abstract available
Alopecia • Dermatopathology • Immunology
January 05, 2026
Update on low dose oral minoxidil
(AAD 2026)
- No abstract available
January 05, 2026
F064 Hair Loss in Women
(AAD 2026)
- "Utilize best practices for low dose oral minoxidil; oral, topical or intralesional forms of 5a-reductase inhibitors and antiandrogens, and antiinflammatory agents in both non-scarring and scarring alopecias 3. Recognize the safety and efficacy of procedural treatments (PRP, mesotherapy, microneedling, lasers) and hair transplants in both non-scarring and cicatricial alopecia"
Clinical • Aesthetic Medicine • Alopecia • Immunology
January 05, 2026
Low Dose Oral Minoxidil in Elderly Patients as well as those with hypertension or arrhythmias
(AAD 2026)
- No abstract available
Clinical • Cardiovascular • Hypertension
January 05, 2026
Minoxidil update
(AAD 2026)
- No abstract available
January 05, 2026
F015 Follicular Rescue in Scarring Alopecias: Treating to Halt Disease Progression and Grow Hair
(AAD 2026)
- "Utilization of new therapies, like PRP and microneedling as well as indications for adding treatments like oral minoxidil for adjunct treatment, will also be discussed...Demonstrate the signs of treatable scarring alopecias using dermoscopic and pathologic cues 3. Discuss the therapeutic ladder of treatments to treat scarring alopecias with familiar and new therapies"
Alopecia • Cognitive Disorders • Fibrosis • Immunology • Lichen Planus
January 05, 2026
S010 Alopecia: Work-up and Treatment
(AAD 2026)
- "Treatment modalities including minoxidil, janus kinase inhibitors, platelet rich plasma therapy, and hair transplantation will be discussed...3. Formulate treatment plans that are evidence-based and patient-oriented, using shared decision making."
Aesthetic Medicine • Alopecia • Fibrosis • Immunology • Lichen Planus
January 05, 2026
U007 Hair Transplantation
(AAD 2026)
- "DESCRIPTION During the session we will discuss the latest role of medical therapy to optimize density from hair transplantation including - PRP, low level light therapy, high energy laser hair stimulation, oral and topical minoxidil and finasteride...Recognize the role of FUE vs FUT as donor harvesting techniques 3. Implement hair transplantation into a busy dermatology practice"
Aesthetic Medicine • Alopecia • Anesthesia • Dermatology • Immunology • Transplantation
February 08, 2026
Microneedles self-implanting Astragalus polysaccharides-hybridized composite hydrogel combined with minoxidil to enhance in situ anti-androgenetic alopecia.
(PubMed, Drug Deliv Transl Res)
- "Concurrently, MDX@MOF-APS/cHA-MNs significantly prolong drug retention time in the skin, effectively improving hair coverage and growth rate in androgenetic alopecia mice. In summary, APS emerges as a clinical candidate for treating androgenetic alopecia, while novel microneedles with unique composition and structure enrich topical delivery strategies."
Journal • Alopecia • Immunology
February 08, 2026
Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study.
(PubMed, J Am Acad Dermatol)
- "Adverse effects from combination therapy are generally mild and managed outpatient. Concomitant use of >1 blood pressure-altering drugs increases risk of hypotension-related symptoms. Simultaneous initiation may reduce risk of hypertrichosis without increasing risk of hypotension-related effects."
Journal • Retrospective data • Alopecia • Dermatology • Hypotension • Immunology
February 06, 2026
Androgenetic alopecia: an international expert view on the aetiopathogenesis, quality of life and current and emerging therapeutic approaches.
(PubMed, Eur J Dermatol)
- "Recent research evidenced that targeting the hair follicle and the surrounding tissue, rather than solely relying on solutions offered by minoxidil, finasteride, or other products, provides a safe and highly beneficial improvement of AGA. These innovations offer compelling early intervention strategies, potentially delaying reliance on lifelong pharmaceutical regimens and optimizing the overall patient journey and quality of life. In addition to current treatment options of AGA, novel topical non-pharmacological therapeutic options are available, helping to safely and efficiently treat this multifactorial hair condition."
HEOR • Journal • Review • Alopecia • Immunology
January 31, 2026
Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata
(ChiCTR)
- P=N/A | N=150 | Completed | Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
New trial • Alopecia • Dermatology • Immunology
February 03, 2026
Review on natural remedies for hair growth promotion with a focus on rosemary.
(PubMed, Dermatol Reports)
- "In contrast to conventional treatments like minoxidil and other chemical remedies, which often come with undesirable side effects such as scalp irritation, systemic effects, and potential dependency, rosemary offers a more natural alternative with fewer adverse effects...These findings suggest R. officinalis leaf extract may serve as a viable natural alternative for hair loss treatment, warranting further investigation into its mechanisms and long-term benefits. This review highlights the need for further research into natural remedies, as well as rosemary's long-term efficacy and safety, positioning it as a promising candidate for those seeking a safer approach to hair restoration."
Journal • Alopecia • Immunology
February 02, 2026
Rare Coexistence of Monilethrix and Trichorrhexis Nodosa in a Pediatric Patient: A Case Report.
(PubMed, Clin Case Rep)
- "Subsequently, the diagnosis of concurrent monilethrix and TN was made for the patient. We observed minimal clinical improvement after treatment with low-dose oral and topical minoxidil."
Journal • Genetic Disorders • Pediatrics
February 02, 2026
Topical Cetirizine in Androgenetic Alopecia: A Preliminary Study.
(PubMed, Skin Appendage Disord)
- "Exclusion criteria included recent use of minoxidil, finasteride, or other antiandrogenic therapies. Despite limitations, this report provides additional real-world data supporting cetirizine as a potential therapy in AGA. Larger randomized controlled studies with longer follow-up are needed to establish efficacy, durability, and mechanism of action."
Journal • Alopecia • Immunology
February 02, 2026
Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study.
(PubMed, J Dermatolog Treat)
- "Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males with androgenetic alopecia (AGA). Steady state was achieved for both drugs after 7 days. The favorable safety profile and reduced systemic finasteride exposure position CG2001 as a promising alternative, supporting further clinical development in a phase IIa trial, and provide a pharmacokinetic foundation for subsequent efficacy trials in patients with AGA."
Clinical • Journal • P1 data • PK/PD data • Addiction (Opioid and Alcohol) • Alopecia • Immunology
January 31, 2026
Efficacy and safety of 5% minoxidil topical foam in the treatment of male androgenic alopecia areata in the real world: a multicenter, prospective, self-controlled clinical study
(ChiCTR)
- P4 | N=72 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital; China-Japan Friendship Hospital
New P4 trial • Alopecia • Dermatology • Immunology
January 31, 2026
Antiviral drugs for treating alopecia areata
(ChiCTR)
- P=N/A | N=184 | Not yet recruiting | Sponsor: Beijing Hospital; Beijing Hospital
New trial • Alopecia • Dermatology • Immunology
January 31, 2026
A prospective, multicenter, randomized, parallel-controlled clinical trial evaluating the safety and efficacy of a laser hair growth device for improving scalp and hair appearance
(ChiCTR)
- P=N/A | N=160 | Not yet recruiting | Sponsor: Fudan University Affiliated Huashan Hospital; Doctor Laser Technology (Beijing) Co., Ltd
New trial
January 29, 2026
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia
(clinicaltrials.gov)
- P=N/A | N=18 | Recruiting | Sponsor: Fujian Medical University Union Hospital
New trial • Alopecia • Dermatology • Immunology
January 30, 2026
Fibroblast Growth Factor-7 and Hair Biology: Bridging Basic Science and Therapeutic Applications.
(PubMed, Curr Issues Mol Biol)
- "Alopecia profoundly impacts psychological well-being and quality of life, yet current therapeutic options such as minoxidil and finasteride exhibit limited efficacy...Future directions include the development of engineering to extend the systemic half-life, advanced delivery systems, and gene or mRNA-based therapeutic approaches. Thus, the FGF-7/FGFR2b axis is a highly compelling molecular target for next-generation hair regeneration therapies."
Journal • Review • Alopecia • Immunology • FGF • FGF7 • IGF1
1 to 25
Of
1786
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72